title: Treatment of Alzheimer's disease. New developments.
abstract: Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzheimer's disease treatment. They produce significant improvement on cognitive as well as non-cognitive function for a period up to one year during the first three years period following clinical onset. The magnitude of cognitive improvements is similar for different ChEI; however, differences are seen with regard to incidence and severity of side effects, incidence of drop-outs, optimal ChE inhibition, pharmacokinetics properties and mode of administration.
authors.affiliation: Department of Geriatrics, University Hospitals of Geneva, Geneva Medical School, Route de Mon-Idée, CH-1226 Thônex, Geneva.
authors.forename: E
authors.initials: E
authors.lastname: Giacobini
authors.forename: J P
authors.initials: JP
authors.lastname: Michel
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000975:Antioxidants / Q000009:adverse effects / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008297:Male; D018721:Muscarinic Agonists / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists